Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim S, King J, Hines OJ, Girgis M, Sadeghi S, Olevsky O, Wong D, Yonemoto L, Siney AM, Kelly K, Kivork C, Tseng CH, Radu CG, Dawson DW, Donahue TR.
Wainberg ZA, et al. Among authors: olevsky o.
Nat Commun. 2026 Jan 31. doi: 10.1038/s41467-026-68976-2. Online ahead of print.
Nat Commun. 2026.
PMID: 41620440
Free article.